{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Answers from the Lab","title":"Lipid assay improves cardiovascular risk prediction: Jeff Meeusen, Ph.D.","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/1c2fd056\"></iframe>","width":"100%","height":180,"duration":521,"description":"Jeff Meeusen, Ph.D., explains how Mayo Clinic Laboratories' new MI-Heart Ceramides assay helps guide the management of patients with mildly to moderately high cholesterol. The test measures levels of lipids beyond cholesterol that boost cardiovascular risk.Show notes(00:31)Could you provide us a little bit about your background? (01:20)Could you give us a brief overview of this assay? (02:45)What patients should have this test and when should it be performed? (04:25)Could you talk a little bit about alternative test options and how they compare to our ceramides test? (05:58)Can you go a little bit further into how these results can impact patient care and how you may monitor patients in the future with this testing?","thumbnail_url":"https://img.transistorcdn.com/jhRCftFebxnTMwoIbA_WoqrSKwFRD_Y2kbh0JDjhx14/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9lYjNj/ZDc0NTE0MWNlOWRl/YzRiN2Q3NDg2Mjg5/YWE4MS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}